Pralatrexate Patent Expiration
Pralatrexate is Used for treating patients with relapsed or refractory peripheral T-cell lymphoma. It was first introduced by Acrotech Biopharma Inc
Pralatrexate Patents
Given below is the list of patents protecting Pralatrexate, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Folotyn | US7622470 | Treatment of T-cell lymphoma using 10-propargyl-10-deazaaminopterin |
May 31, 2025
(Expired) | Acrotech Biopharma |
| Folotyn | US8299078 | Treatment of T-cell lymphoma using 10-propargyl-10-deazaaminopterin |
May 31, 2025
(Expired) | Acrotech Biopharma |
| Folotyn | US6028071 | Purified compositions of 10-propargyl-10-deazaaminopterin and methods of using same in the treatment of tumors |
Jul 16, 2022
(Expired) | Acrotech Biopharma |
Pralatrexate's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Pralatrexate:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies | Jennifer Amengual | NA |
TERMINATED
(Sep 1, 2026)
| PHASE1, PHASE2 |
| Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas | City of Hope Medical Center | NA |
ACTIVE NOT RECRUITING
(May 1, 2026)
| PHASE1, PHASE2 |
| Pralatrexate With Bendamustine and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma | Fred Hutchinson Cancer Center | NA |
RECRUITING
(May 1, 2026)
| PHASE1, PHASE2 |